The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference
Open accessAbstract
To cite this article: Schram ME, Spuls PI, Leeflang MMG, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy 2012; 67: 99–106. Background: Demonstration of adequate reliability and validity is sufficient for concluding that an instrument is applicable for descriptive and predictive purposes, but before we can confidently use an outcome measure in clinical trials, the responsiveness (synonymous with sensitivity to change) and minimal clinically important difference (MCID) should be known. With this study, we aimed to assess responsiveness and MCID of four outcome measures used in atopic eczema: the Severity Scoring of Atopic Dermatitis (SCORAD), the objective SCORAD, Eczema Area and Severity Index (EASI), and the Patient‐Oriented Eczema Measure (POEM). Methods: Data of three randomized controlled trials were used. To demonstrate responsiveness, we plotted receiver operating characteristic (ROC) curves. MCID was estimated using mean change scores of patients that showed a relevant improvement. Bland and Altman methods were used to quantify the limits of agreement. Results: Area under the ROC curve for the SCORAD was 0.70 [95% confidence interval (CI): 0.61–0.78], for the objective SCORAD, 0.73 (95% CI: 0.70–0.77), for the EASI, 0.67 (95% CI: 0.60–0.76), and for the POEM, 0.67 (95% CI: 0.59–0.75). Scores above 0.70 represent a fair responsiveness. The MCID was 8.7 points for the SCORAD, 8.2 for the objective SCORAD, 6.6 for the EASI, and 3.4 for the POEM. Conclusion: The objective SCORAD and SCORAD showed a fair responsiveness. The MCIDs are an important prerequisite for the interpretation of published eczema trials and for the planning/sample size estimation of future trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
Hosmer, D. W., & Lemeshow, S. (2000) · doi:10.1002/0471722146 · Cited by 20,302
Jaeschke, R., Singer, J., & Guyatt, G. H. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90005-6 · Cited by 4,982
Mokkink, L. B., Terwee, C. B., Patrick, D. L., Alonso, J., Stratford, P. W., Knol, D. L., Bouter, L. M., & de Vet, H. C. W. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.02.006 · Cited by 4,465 · cited 3×
“The COSMIN does not provide a consensus on how to calculate the MCID.”
MethodBeasley, R. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07302-9 · Cited by 3,389
Revicki, D., Hays, R. D., Cella, D., & Sloan, J. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.03.012 · Cited by 2,362
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,273
Mokkink, L. B., Terwee, C. B., Knol, D. L., Stratford, P. W., Alonso, J., Patrick, D. L., Bouter, L. M., & de Vet, H. C. (2010) · BMC Medical Research Methodology · doi:10.1186/1471-2288-10-22 · Cited by 1,834
Defining clinically meaningful change in health-related quality of life
Crosby, R. D., Kolotkin, R. L., & Williams, G. R. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(03)00044-1 · Cited by 1,332
Measuring the whole or the parts?
Beaton, D. E., Katz, J. N., Fossel, A. H., Wright, J. G., Tarasuk, V., & Bombardier, C. (2001) · Journal of Hand Therapy · doi:10.1016/s0894-1130(01)80043-0 · Cited by 1,306
Charman, C. R., Venn, A. J., & Williams, H. C. (2004) · Archives of Dermatology · doi:10.1001/archderm.140.12.1513 · Cited by 660
The Burden of Atopic Dermatitis: Impact on the Patient, Family, and Society
Carroll, C. L., Balkrishnan, R., Feldman, S. R., Fleischer, A. B., & Manuel, J. C. (2005) · Pediatric Dermatology · doi:10.1111/j.1525-1470.2005.22303.x · Cited by 489
Beaton, D. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00407-3 · Cited by 487
Responsiveness and validity in health status measurement: a clarification
Guyatt, G. H., Deyo, R. A., Charlson, M., Levine, M. N., & Mitchell, A. (1989) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(89)90128-5 · Cited by 480 · cited 1×
“Demonstration of adequate validity and reliability is sufficient for concluding that an instrument is applicable for descriptive and predictive purposes, but before we can confidently use an outcome measure in clinical trials, the responsiveness and minimal clinically important difference (MCID) should be known (7, 8).”
BackgroundWhat are the best outcome measurements for atopic eczema? A systematic review
Schmitt, J., Langan, S., & Williams, H. C. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.08.011 · Cited by 388 · cited 1×
“However, a recently published systematic review (3) indicated that only three of these measures have shown adequate validity and reliability: the Eczema Area and Severity Index (EASI), the Severity Scoring of Atopic Dermatitis (SCORAD), of which there is a variant called the objective SCORAD, and the Patient-Oriented…”
BackgroundA randomized trial of methotrexate versus azathioprine for severe atopic eczema
Schram, M. E., Roekevisch, E., Leeflang, M. M. G., Bos, J. D., Schmitt, J., & Spuls, P. I. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.03.024 · Cited by 260
Self-citationSchmitt, J. M., Schäkel, K., Fölster‐Holst, R., Bauer, A., Oertel, R., Augustin, M., Aberer, W., Luger, T. A., & Meurer, M. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09561.x · Cited by 136
Self-citationde Winter, A. F., Heemskerk, M., Terwee, C. B., Jans, M. P., Devillé, W. L. J. M., van Schaardenburg, D., Scholten, R. J. P. M., & Bouter, L. M. (2004) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-5-18 · Cited by 105
Eczema area and severity index (EASI): A new tool to evaluate atopic dermatitis
Tofte, S. J. (1998) · Journal of the European Academy of Dermatology and Venereology · doi:10.1016/s0926-9959(98)95291-6 · Cited by 102
Quality‐of‐life measurements in the evaluation of treatment: proposed guidelines.
FLETCHER, A. E. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04439.x · Cited by 39
Breuer, K., Braeutigam, M., Kapp, A., & Werfel, T. (2004) · Dermatology · doi:10.1159/000080855 · Cited by 37
Schmitt, J. M., Meurer, M., Schwanebeck, U., Grählert, X., & Schäkel, K. (2008) · Dermatology · doi:10.1159/000151355 · Cited by 12
Self-citation
Cited by
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M., Bieber, T., Rocklin, R., Ming, J. E., Ren, H., Kao, R., Simpson, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,421
Guidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Chamlin, S. L., Feldman, S. R., Hanifin, J. M., Simpson, E. L., Berger, T. G., Bergman, J. N., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.10.010 · Cited by 1,277
Blauvelt, A., de Bruin-Weller, M., Gooderham, M., Cather, J. C., Weisman, J., Pariser, D., Simpson, E. L., Papp, K. A., Hong, H. C.-H., Rubel, D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31191-1 · Cited by 1,261
Schoemaker, A. A., Sprikkelman, A. B., Grimshaw, K. E., Roberts, G., Grabenhenrich, L., Rosenfeld, L., Siegert, S., Dubakiene, R., Rudzeviciene, O., Reche, M., et al. (2015) · Allergy · doi:10.1111/all.12630 · Cited by 484
Metadata
- Authors
- Schram, M. E., Spuls, P. I., Leeflang, M. M. G., Lindeboom, R., Bos, J. D., & Schmitt, J.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2011-09-27
- Volume
- 67
- Issue
- 1
- Pages
- 99-106
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W1583257755
- Cited by
- 383
- References
- 23
- FWCI
- 11.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.